BrainsWay Ltd. (NASDAQ: BWAY) Stock Competitors & Peer Comparison
See BWAY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BWAY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BWAY | $14.41 | +1.77% | 565.2M | 36.61 | $0.39 | N/A |
| ALC | $68.43 | -1.00% | 33.4B | 21.52 | $3.18 | +0.52% |
| STE | $215.09 | -1.53% | 21B | 20.64 | $10.42 | +1.20% |
| QDEL | $12.64 | -5.53% | 861.9M | 9.43 | $1.34 | N/A |
| MLAB | $123.91 | +0.14% | 693.4M | 12.50 | $9.91 | +0.51% |
| SI | $19.64 | -1.75% | 408.3M | -11.38 | -$1.73 | N/A |
| MASS | $9.69 | -1.22% | 397.6M | -16.15 | -$0.60 | N/A |
| MOBI | $10.82 | -2.43% | 359.8M | -0.58 | -$18.78 | N/A |
| LAB | $0.73 | +5.06% | 284.6M | -10.39 | -$0.07 | N/A |
| ANIK | $20.88 | -0.76% | 279.4M | 42.61 | $0.49 | N/A |
Stock Comparison
Alcon Inc. (NYSE: ALC)
BWAY vs ALC Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, ALC has a market cap of 33.4B. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while ALC trades at $68.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas ALC's P/E ratio is 21.52. In terms of profitability, BWAY's ROE is +0.13%, compared to ALC's ROE of +0.03%. Regarding short-term risk, BWAY is more volatile compared to ALC. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check ALC's competition here
STERIS plc (NYSE: STE)
BWAY vs STE Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, STE has a market cap of 21B. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while STE trades at $215.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas STE's P/E ratio is 20.64. In terms of profitability, BWAY's ROE is +0.13%, compared to STE's ROE of +0.11%. Regarding short-term risk, BWAY is more volatile compared to STE. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check STE's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
BWAY vs QDEL Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, QDEL has a market cap of 861.9M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while QDEL trades at $12.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas QDEL's P/E ratio is 9.43. In terms of profitability, BWAY's ROE is +0.13%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, BWAY is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check QDEL's competition here
Mesa Laboratories, Inc. (NASDAQ: MLAB)
BWAY vs MLAB Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, MLAB has a market cap of 693.4M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while MLAB trades at $123.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas MLAB's P/E ratio is 12.50. In terms of profitability, BWAY's ROE is +0.13%, compared to MLAB's ROE of +0.03%. Regarding short-term risk, BWAY is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check MLAB's competition here
Shoulder Innovations, Inc. (NYSE: SI)
BWAY vs SI Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, SI has a market cap of 408.3M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while SI trades at $19.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas SI's P/E ratio is -11.38. In terms of profitability, BWAY's ROE is +0.13%, compared to SI's ROE of -0.26%. Regarding short-term risk, BWAY is less volatile compared to SI. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check SI's competition here
908 Devices Inc. (NASDAQ: MASS)
BWAY vs MASS Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, MASS has a market cap of 397.6M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while MASS trades at $9.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas MASS's P/E ratio is -16.15. In terms of profitability, BWAY's ROE is +0.13%, compared to MASS's ROE of -0.25%. Regarding short-term risk, BWAY is more volatile compared to MASS. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check MASS's competition here
Mobia Medical, Inc. Common Stock (NASDAQ: MOBI)
BWAY vs MOBI Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, MOBI has a market cap of 359.8M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while MOBI trades at $10.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas MOBI's P/E ratio is -0.58. In terms of profitability, BWAY's ROE is +0.13%, compared to MOBI's ROE of -15.96%. Regarding short-term risk, BWAY is less volatile compared to MOBI. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check MOBI's competition here
Standard BioTools Inc. (NASDAQ: LAB)
BWAY vs LAB Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, LAB has a market cap of 284.6M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while LAB trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas LAB's P/E ratio is -10.39. In terms of profitability, BWAY's ROE is +0.13%, compared to LAB's ROE of -0.18%. Regarding short-term risk, BWAY is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check LAB's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
BWAY vs ANIK Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, ANIK has a market cap of 279.4M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while ANIK trades at $20.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas ANIK's P/E ratio is 42.61. In terms of profitability, BWAY's ROE is +0.13%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, BWAY is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check ANIK's competition here
Edap Tms S.a. (NASDAQ: EDAP)
BWAY vs EDAP Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas EDAP's P/E ratio is -5.80. In terms of profitability, BWAY's ROE is +0.13%, compared to EDAP's ROE of -3.13%. Regarding short-term risk, BWAY is less volatile compared to EDAP. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check EDAP's competition here
Trinity Biotech plc (NASDAQ: TRIB)
BWAY vs TRIB Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, TRIB has a market cap of 162.2M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while TRIB trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas TRIB's P/E ratio is -0.13. In terms of profitability, BWAY's ROE is +0.13%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, BWAY is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check TRIB's competition here
Nyxoah S.A. (NASDAQ: NYXH)
BWAY vs NYXH Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, NYXH has a market cap of 152.1M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while NYXH trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas NYXH's P/E ratio is -0.60. In terms of profitability, BWAY's ROE is +0.13%, compared to NYXH's ROE of -1.80%. Regarding short-term risk, BWAY is less volatile compared to NYXH. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check NYXH's competition here
Apyx Medical Corporation (NASDAQ: APYX)
BWAY vs APYX Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, APYX has a market cap of 128.4M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while APYX trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas APYX's P/E ratio is -15.25. In terms of profitability, BWAY's ROE is +0.13%, compared to APYX's ROE of -0.79%. Regarding short-term risk, BWAY is more volatile compared to APYX. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check APYX's competition here
SkinHealth Systems Inc. (NASDAQ: SKIN)
BWAY vs SKIN Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, SKIN has a market cap of 89.4M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while SKIN trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas SKIN's P/E ratio is -3.14. In terms of profitability, BWAY's ROE is +0.13%, compared to SKIN's ROE of -0.48%. Regarding short-term risk, BWAY is less volatile compared to SKIN. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check SKIN's competition here
Spectral AI, Inc. (NASDAQ: MDAI)
BWAY vs MDAI Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, MDAI has a market cap of 50.3M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while MDAI trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas MDAI's P/E ratio is -3.51. In terms of profitability, BWAY's ROE is +0.13%, compared to MDAI's ROE of +1.21%. Regarding short-term risk, BWAY is less volatile compared to MDAI. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check MDAI's competition here
DarioHealth Corp. (NASDAQ: DRIO)
BWAY vs DRIO Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, DRIO has a market cap of 50.2M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while DRIO trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas DRIO's P/E ratio is -1.17. In terms of profitability, BWAY's ROE is +0.13%, compared to DRIO's ROE of +1.04%. Regarding short-term risk, BWAY is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check DRIO's competition here
HeartBeam, Inc. (NASDAQ: BEAT)
BWAY vs BEAT Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, BEAT has a market cap of 23.3M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while BEAT trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas BEAT's P/E ratio is -0.82. In terms of profitability, BWAY's ROE is +0.13%, compared to BEAT's ROE of -6.87%. Regarding short-term risk, BWAY is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check BEAT's competition here
HeartBeam, Inc. (NASDAQ: BEATW)
BWAY vs BEATW Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, BEATW has a market cap of 5.5M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while BEATW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas BEATW's P/E ratio is -0.01. In terms of profitability, BWAY's ROE is +0.13%, compared to BEATW's ROE of -6.87%. Regarding short-term risk, BWAY is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check BEATW's competition here
WORK Medical Technology Group Ltd. Class A (NASDAQ: WOK)
BWAY vs WOK Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, WOK has a market cap of 4.9M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while WOK trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas WOK's P/E ratio is N/A. In terms of profitability, BWAY's ROE is +0.13%, compared to WOK's ROE of -0.19%. Regarding short-term risk, BWAY is less volatile compared to WOK. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check WOK's competition here
QTREX Quantum Ltd. Warrant (NASDAQ: QTEXW)
BWAY vs QTEXW Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, QTEXW has a market cap of 3.5M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while QTEXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas QTEXW's P/E ratio is -0.01. In terms of profitability, BWAY's ROE is +0.13%, compared to QTEXW's ROE of N/A. Regarding short-term risk, BWAY is less volatile compared to QTEXW. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check QTEXW's competition here
iTonic Holdings Ltd. (NASDAQ: ITOC)
BWAY vs ITOC Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, ITOC has a market cap of 2.9M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while ITOC trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas ITOC's P/E ratio is -0.99. In terms of profitability, BWAY's ROE is +0.13%, compared to ITOC's ROE of -0.94%. Regarding short-term risk, BWAY is less volatile compared to ITOC. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check ITOC's competition here
ENvue Medical, Inc. (NASDAQ: FEED)
BWAY vs FEED Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, FEED has a market cap of 2.8M. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while FEED trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas FEED's P/E ratio is -0.03. In terms of profitability, BWAY's ROE is +0.13%, compared to FEED's ROE of -0.60%. Regarding short-term risk, BWAY is less volatile compared to FEED. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check FEED's competition here
Tivic Health Systems, Inc. (NASDAQ: TIVC)
BWAY vs TIVC Comparison September 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 565.2M. In comparison, TIVC has a market cap of 279.2K. Regarding current trading prices, BWAY is priced at $14.41 on the NASDAQ, while TIVC trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 36.61, whereas TIVC's P/E ratio is -0.04. In terms of profitability, BWAY's ROE is +0.13%, compared to TIVC's ROE of -1.65%. Regarding short-term risk, BWAY is less volatile compared to TIVC. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check TIVC's competition here